Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27812820 | 0.77 | HTR2C (0.58) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5584542 | 0.77 | HTR2C (0.73) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5020033 | 0.75 | HTR1A (0.67) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15226931 | 0.75 | SLC6A2 (0.51) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19703133 | 0.75 | HTR2C (0.57) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5584737 | 0.75 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4HTR6 | |
| SCHEMBL5937367 | 0.75 | HTR2C (0.45) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27725541 | 0.75 | PLAT (0.43) | HTR2CSLC6A2SLC6A4HTR6 | |
| Hydrochloric Acid SCHEMBL21855666 | 0.74 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4HTR6 | |
| Hydrochloric Acid SCHEMBL31109384 | 0.74 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR1A 1/4885SLC6A2 21/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR1A 1/4885SLC6A2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.